Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin

The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojya, Sanae, Shiohira, Hideo, Sunagawa, Yoshitsugu, Tsuneyoshi, Shoji, Kohagura, Kentaro, Ohya, Yusuke, Yonaha, Fusako, Hokama, Nobuo, Nakamura, Katsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303865/
https://www.ncbi.nlm.nih.gov/pubmed/32577250
http://dx.doi.org/10.1002/ccr3.2774
Descripción
Sumario:The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in patients receiving CAPD.

Ejemplares similares